SG10201913796UA - Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number: SG10201913796UA
Authority: SG; Singapore
Prior art keywords: ynoyl; pyrazin; imidazo; pyrrolidin; benzamide
Prior art date: 2015-07-02

Application number

SG10201913796UA

Inventor

Fritz Blatter

Tim Ingallinera

Tjeerd Barf

Edwin Aret

Cecile Krejsa

Jerry Evarts

Original Assignee

Acerta Pharma Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-02

Filing date

2016-07-01

Publication date

2020-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913796U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-01 Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv

2020-03-30 Publication of SG10201913796UA publication Critical patent/SG10201913796UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)

SG10201913796UA 2015-07-02 2016-07-01 Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide SG10201913796UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562188468P	2015-07-02	2015-07-02
US201562271708P	2015-12-28	2015-12-28

Publications (1)

Publication Number	Publication Date
SG10201913796UA true SG10201913796UA (en)	2020-03-30

Family

ID=56363881

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201913796UA SG10201913796UA (en)	2015-07-02	2016-07-01	Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (30)

Country	Link
US (7)	US9796721B2 (en)
EP (4)	EP3954690B1 (en)
JP (3)	JP6829215B2 (en)
KR (2)	KR102688052B1 (en)
CN (2)	CN108349978B (en)
AU (3)	AU2016286548B2 (en)
CA (1)	CA2991096A1 (en)
CL (1)	CL2017003445A1 (en)
CY (3)	CY1124519T1 (en)
DK (3)	DK3613745T3 (en)
ES (3)	ES2946489T3 (en)
FI (1)	FI3954690T3 (en)
HK (1)	HK1250511A1 (en)
HR (3)	HRP20230417T1 (en)
HU (3)	HUE062258T2 (en)
IL (3)	IL293821A (en)
LT (3)	LT3317281T (en)
MA (1)	MA50817B1 (en)
MD (1)	MD3317281T2 (en)
MX (2)	MX2020014163A (en)
MY (1)	MY193514A (en)
PL (3)	PL3954690T3 (en)
PT (3)	PT3613745T (en)
RS (3)	RS60411B1 (en)
RU (1)	RU2018103913A (en)
SG (1)	SG10201913796UA (en)
SI (3)	SI3613745T1 (en)
SM (3)	SMT202100597T1 (en)
WO (1)	WO2017002095A1 (en)
ZA (2)	ZA201800329B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT202100674T1 (en) *	2014-08-11	2022-01-10	Acerta Pharma Bv	Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
PL3954690T3 (en)	2015-07-02	2023-08-14	Acerta Pharma B.V.	Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CN113416194A (en)	2016-10-05	2021-09-21	杭州领业医药科技有限公司	ACP-196 crystal form, preparation method and pharmaceutical composition thereof
WO2018115965A1 (en) *	2016-12-23	2018-06-28	Acerta Pharma Bv	Solid forms of imidazopyrazine compounds
WO2018148961A1 (en) *	2017-02-20	2018-08-23	杭州领业医药科技有限公司	Crystal form of acp-196 salt and preparation method, pharmaceutical composition, and use thereof
MX2019011496A (en)	2017-03-27	2020-01-23	Tesaro Inc	Niraparib compositions.
SG11201908977SA (en) *	2017-03-27	2019-10-30	Tesaro Inc	Niraparib formulations
US10717740B2 (en)	2017-06-13	2020-07-21	Dr. Reddy's Laboratories Limited.	Solid forms of acalabrutinib and process for preparation thereof
WO2019041026A1 (en) *	2017-08-29	2019-03-07	Apotex Inc.	Novel crystalline forms of acalabrutinib
MX2020003760A (en)	2017-09-26	2020-07-29	Tesaro Inc	Niraparib formulations.
WO2019105359A1 (en) *	2017-11-30	2019-06-06	苏州科睿思制药有限公司	Crystal form of acalabrutinib, preparation method therefor and application thereof
CN111527089B (en) *	2018-01-05	2021-03-12	苏州科睿思制药有限公司	Novel crystal form of Acaraburtinib and preparation method and application thereof
WO2019159097A1 (en) *	2018-02-14	2019-08-22	Sun Pharmaceutical Industries Limited	Crystalline polymorphic forms of acalabrutinib
US20210087195A1 (en) *	2018-04-26	2021-03-25	Crystal Pharmaceutical (Suzhou) Co., Ltd.	New crystal form of acalbrutinib, preparation method therefor and use thereof
EP3587421A1 (en)	2018-06-29	2020-01-01	Sandoz AG	Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
AU2019332882B2 (en)	2018-08-29	2022-01-27	Acerta Pharma B.V.	Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
WO2020053795A2 (en)	2018-09-13	2020-03-19	Fresenius Kabi Oncology Ltd.	Process for the preparation of acalabrutinib and its intermediates
WO2020065667A1 (en)	2018-09-25	2020-04-02	Cipla Limited	Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
EP3947386A1 (en)	2019-03-27	2022-02-09	Assia Chemical Industries Ltd	Solid state forms of acalabrutinib
WO2020225831A1 (en) *	2019-05-09	2020-11-12	Msn Laboratories Private Limited, R&D Center	Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (en) *	2019-12-31	2021-07-08	苏州科睿思制药有限公司	New crystal form of acalabrutinib, preparation method therefor and use thereof
WO2021239893A1 (en)	2020-05-29	2021-12-02	Bend Research, Inc.	Amorphous solid dispersion of acalabrutinib
KR20230027201A (en) *	2020-06-19	2023-02-27	아세르타 파마. 비.브이.	Acalabrutinib Maleate Dosage Form
CN112028896A (en) *	2020-10-14	2020-12-04	奥锐特药业(天津)有限公司	Novel crystal form of acatinib and preparation method thereof
US20240315978A1 (en) *	2021-01-13	2024-09-26	Natco Pharma Limited	Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (en)	2021-08-03	2023-02-09	Syros Pharmaceuticals, Inc.	Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023205279A1 (en) *	2022-04-19	2023-10-26	The Johns Hopkins University	Improved raman spectroscopy with the addition of aromatic compounds
WO2024164066A1 (en) *	2023-02-09	2024-08-15	Apotex Inc	Crystalline forms of acalabrutinib maleate

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001081031A (en)	1999-08-30	2001-03-27	Schering Ag	Benzamide derivative-containing preparation having improved solubility and oral adsorption
JP2003509427A (en)	1999-09-17	2003-03-11	アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー	Kinase inhibitors as therapeutic agents
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
JP4916883B2 (en)	2003-10-15	2012-04-18	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Imidazopyrazine tyrosine kinase inhibitor
EP2308879A1 (en)	2004-04-02	2011-04-13	OSI Pharmaceuticals, Inc.	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
ITMI20051231A1 (en)	2005-06-29	2006-12-30	Pharmaproducts Uk Ltd	PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND FOLINATED CALCIUM FOR THE TREATMENT OF ORAL CABLE AFFECTIONS
CA2616416A1 (en)	2005-09-09	2007-05-03	Labopharm, Inc.	Trazodone composition for once a day adminisitiation
DE602006021608D1 (en)	2005-11-17	2011-06-09	Osi Pharm Inc	CONDENSED BICYCLIC MTOR INHIBITORS
PE20070855A1 (en)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
AR057960A1 (en)	2005-12-02	2007-12-26	Osi Pharm Inc	BICYCLE PROTEIN QUINASE INHIBITORS
US7651687B2 (en)	2006-03-13	2010-01-26	Osi Pharmaceuticals, Inc.	Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
PT2529622T (en)	2006-09-22	2018-04-24	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
SG10201508035TA (en)	2007-03-28	2015-10-29	Pharmacyclics Inc	Inhibitors of bruton's tyrosine kinase
US20120101114A1 (en)	2007-03-28	2012-04-26	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
US8088824B2 (en) *	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
RU2010128239A (en)	2007-12-13	2012-01-20	Новартис АГ (CH)	COMBINATIONS OF THERAPEUTIC MEDICINES FOR THE TREATMENT OF CANCER
US9095592B2 (en)	2008-11-07	2015-08-04	The Research Foundation For The State University Of New York	Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en)	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
EP2424368B1 (en)	2009-04-29	2014-12-31	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
CA2787291C (en)	2010-02-08	2016-04-19	Msd Oss B.V.	8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
CN102190594A (en) *	2010-03-17	2011-09-21	上海医药工业研究院	Agomelatine hydrogen chloride hydrate and preparation method thereof
UY33288A (en)	2010-03-25	2011-10-31	Glaxosmithkline Llc	INDOLINE DERIVATIVES INHIBITORS OF THE PROTEIN QUINASA R OF THE ENDOPLASMATIC RETICLE
ES2948312T3 (en)	2010-05-31	2023-09-08	Ono Pharmaceutical Co	Purinone derivative as a Btk kinase inhibitor
CA3007788C (en)	2010-06-03	2020-03-10	Pharmacyclics Llc	The use of inhibitors of bruton's tyrosine kinase (btk)
US20120053189A1 (en)	2010-06-28	2012-03-01	Pharmacyclics, Inc.	Btk inhibitors for the treatment of immune mediated conditions
EP2710007B1 (en)	2011-05-17	2019-12-11	The Regents of The University of California	Kinase inhibitors
MX2014000130A (en)	2011-06-28	2014-05-01	Pharmacyclics Inc	Methods and compositions for inhibition of bone resorption.
EA201490265A1 (en)	2011-07-13	2014-12-30	Фармасайкликс, Инк.	BLUTON TYROSINKINASE INHIBITORS
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
MY192354A (en) *	2011-07-19	2022-08-17	Merck Sharp & Dohme	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
AU2012285988B2 (en)	2011-07-19	2017-05-25	Merck Sharp & Dohme B.V.	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors
CA3110966A1 (en)	2011-10-19	2013-04-25	Pharmacyclics Llc	Use of inhibitors of bruton's tyrosine kinase (btk)
US20140212425A1 (en)	2011-12-05	2014-07-31	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
BR112014028841B1 (en) *	2012-05-23	2021-01-12	Nerviano Medical Sciences S.R.L.	CRYSTALLINE FORMS 1 AND 2, PHARMACEUTICAL COMPOSITION, USE OF CRYSTALLINE 1 FOR THE TREATMENT OF A DISEASE STATABLE BY ALK INHIBITION AND PROCESS FOR THE PREPARATION OF N- [5- (3,5-DIFLUORO-BENZIL) -1H- INDAZOL-3-IL] -4- (4-METHYLPIPERAZIN-1-IL) -2- (TETRA-HYDRO-PYRAN-4-ILAMINE) - BENZAMIDE
EP2948458B1 (en)	2013-01-23	2019-05-01	Merck Sharp & Dohme Corp.	Btk inhibitors
CN105073115A (en)	2013-03-14	2015-11-18	药品循环有限责任公司	Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
WO2014143807A2 (en)	2013-03-15	2014-09-18	Stromatt Scott	Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
KR20150141971A (en)	2013-04-08	2015-12-21	파마싸이클릭스 엘엘씨	Ibrutinib combination therapy
AP2015008750A0 (en)	2013-04-08	2015-09-30	Bayer Pharma AG	Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015018522A1 (en)	2013-08-06	2015-02-12	Oncoethix Sa	Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015057992A1 (en) *	2013-10-16	2015-04-23	Izumi Raquel	Btk inhibitors for hematopoietic mobilization
EP3076974A1 (en)	2013-12-05	2016-10-12	Acerta Pharma B.V.	Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US9556150B2 (en)	2013-12-13	2017-01-31	Hoffmann-La Roche Inc.	Inhibitors of bruton's tyrosine kinase
WO2015110923A2 (en)	2014-01-21	2015-07-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
FR3021783B1 (en)	2014-06-02	2016-05-13	Morpho	METHOD FOR VALIDATING THE AUTHENTICITY OF A HUMAN BODY ELEMENT
PL3954690T3 (en) *	2015-07-02	2023-08-14	Acerta Pharma B.V.	Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

2016
- 2016-07-01 PL PL21182842.1T patent/PL3954690T3/en unknown
- 2016-07-01 IL IL293821A patent/IL293821A/en unknown
- 2016-07-01 RU RU2018103913A patent/RU2018103913A/en unknown
- 2016-07-01 PL PL19196939T patent/PL3613745T3/en unknown
- 2016-07-01 AU AU2016286548A patent/AU2016286548B2/en active Active
- 2016-07-01 SI SI201631364T patent/SI3613745T1/en unknown
- 2016-07-01 EP EP21182842.1A patent/EP3954690B1/en active Active
- 2016-07-01 CN CN201680050713.6A patent/CN108349978B/en active Active
- 2016-07-01 ES ES21182842T patent/ES2946489T3/en active Active
- 2016-07-01 DK DK19196939.3T patent/DK3613745T3/en active
- 2016-07-01 ES ES16735945T patent/ES2797987T3/en active Active
- 2016-07-01 HU HUE21182842A patent/HUE062258T2/en unknown
- 2016-07-01 US US15/200,875 patent/US9796721B2/en active Active
- 2016-07-01 EP EP19196939.3A patent/EP3613745B1/en active Active
- 2016-07-01 SI SI201630805T patent/SI3317281T1/en unknown
- 2016-07-01 DK DK16735945.4T patent/DK3317281T3/en active
- 2016-07-01 LT LTEP16735945.4T patent/LT3317281T/en unknown
- 2016-07-01 RS RS20200681A patent/RS60411B1/en unknown
- 2016-07-01 EP EP23157244.7A patent/EP4209493A1/en active Pending
- 2016-07-01 LT LTEP19196939.3T patent/LT3613745T/en unknown
- 2016-07-01 SM SM20210597T patent/SMT202100597T1/en unknown
- 2016-07-01 PT PT191969393T patent/PT3613745T/en unknown
- 2016-07-01 IL IL274066A patent/IL274066B/en unknown
- 2016-07-01 RS RS20230367A patent/RS64195B1/en unknown
- 2016-07-01 PL PL16735945T patent/PL3317281T3/en unknown
- 2016-07-01 FI FIEP21182842.1T patent/FI3954690T3/en active
- 2016-07-01 KR KR1020187003310A patent/KR102688052B1/en active Active
- 2016-07-01 RS RS20211291A patent/RS62455B1/en unknown
- 2016-07-01 MY MYPI2017001918A patent/MY193514A/en unknown
- 2016-07-01 MA MA50817A patent/MA50817B1/en unknown
- 2016-07-01 SG SG10201913796UA patent/SG10201913796UA/en unknown
- 2016-07-01 HR HRP20230417TT patent/HRP20230417T1/en unknown
- 2016-07-01 MX MX2020014163A patent/MX2020014163A/en unknown
- 2016-07-01 LT LTEP21182842.1T patent/LT3954690T/en unknown
- 2016-07-01 SI SI201631705T patent/SI3954690T1/en unknown
- 2016-07-01 MD MDE20180479T patent/MD3317281T2/en unknown
- 2016-07-01 HU HUE19196939A patent/HUE056008T2/en unknown
- 2016-07-01 SM SM20200304T patent/SMT202000304T1/en unknown
- 2016-07-01 CN CN202110761102.5A patent/CN113480542A/en active Pending
- 2016-07-01 HU HUE16735945A patent/HUE049989T2/en unknown
- 2016-07-01 EP EP16735945.4A patent/EP3317281B1/en active Active
- 2016-07-01 MX MX2018000179A patent/MX378495B/en unknown
- 2016-07-01 KR KR1020247024480A patent/KR20240115937A/en active Pending
- 2016-07-01 HR HRP20211511TT patent/HRP20211511T1/en unknown
- 2016-07-01 WO PCT/IB2016/053988 patent/WO2017002095A1/en active Application Filing
- 2016-07-01 JP JP2017568182A patent/JP6829215B2/en active Active
- 2016-07-01 SM SM20230165T patent/SMT202300165T1/en unknown
- 2016-07-01 ES ES19196939T patent/ES2895802T3/en active Active
- 2016-07-01 PT PT211828421T patent/PT3954690T/en unknown
- 2016-07-01 DK DK21182842.1T patent/DK3954690T3/en active
- 2016-07-01 PT PT167359454T patent/PT3317281T/en unknown
- 2016-07-01 CA CA2991096A patent/CA2991096A1/en active Pending
2017
- 2017-09-18 US US15/707,508 patent/US10167291B2/en active Active
- 2017-12-28 CL CL2017003445A patent/CL2017003445A1/en unknown
- 2017-12-28 IL IL256633A patent/IL256633B/en active IP Right Grant
2018
- 2018-01-17 ZA ZA2018/00329A patent/ZA201800329B/en unknown
- 2018-07-31 HK HK18109886.8A patent/HK1250511A1/en unknown
- 2018-11-01 US US16/177,927 patent/US10640509B2/en active Active
2020
- 2020-01-16 ZA ZA2020/00300A patent/ZA202000300B/en unknown
- 2020-04-30 US US16/863,033 patent/US11059829B2/en active Active
- 2020-06-10 HR HRP20200934TT patent/HRP20200934T1/en unknown
- 2020-07-02 CY CY20201100611T patent/CY1124519T1/en unknown
- 2020-11-24 AU AU2020277123A patent/AU2020277123B2/en active Active
2021
- 2021-01-21 JP JP2021007689A patent/JP7091494B2/en active Active
- 2021-06-10 US US17/344,233 patent/US20220177476A1/en not_active Abandoned
- 2021-10-19 CY CY20211100904T patent/CY1124815T1/en unknown
2022
- 2022-01-27 US US17/586,726 patent/US11820777B2/en active Active
- 2022-06-15 JP JP2022096907A patent/JP2022120156A/en active Pending
- 2022-12-23 AU AU2022291635A patent/AU2022291635B2/en active Active
2023
- 2023-06-01 CY CY20231100260T patent/CY1126103T1/en unknown
- 2023-10-16 US US18/487,254 patent/US20240199622A1/en active Pending

Also Published As

Publication number	Publication date
US11820777B2 (en)	2023-11-21
PT3317281T (en)	2020-06-18
EP3954690B1 (en)	2023-04-05
HUE049989T2 (en)	2020-11-30
HRP20200934T1 (en)	2020-09-18
KR102688052B1 (en)	2024-07-25
SMT202000304T1 (en)	2020-07-08
HUE062258T2 (en)	2023-10-28
MX2018000179A (en)	2018-06-27
ES2946489T3 (en)	2023-07-19
CN108349978B (en)	2021-07-23
JP2021073235A (en)	2021-05-13
RS62455B1 (en)	2021-11-30
KR20180048593A (en)	2018-05-10
IL293821A (en)	2022-08-01
AU2016286548B2 (en)	2020-12-10
SMT202100597T1 (en)	2021-11-12
AU2016286548A1 (en)	2018-02-01
US20180208596A1 (en)	2018-07-26
US10167291B2 (en)	2019-01-01
US20220348582A1 (en)	2022-11-03
WO2017002095A1 (en)	2017-01-05
MA50817B1 (en)	2021-10-29
PL3317281T3 (en)	2020-11-02
JP2018522877A (en)	2018-08-16
PT3613745T (en)	2021-10-14
SI3317281T1 (en)	2020-08-31
PL3613745T3 (en)	2022-01-31
US20220177476A1 (en)	2022-06-09
HRP20230417T1 (en)	2023-07-07
MY193514A (en)	2022-10-17
AU2020277123B2 (en)	2022-09-29
EP3317281B1 (en)	2020-04-22
CA2991096A1 (en)	2017-01-05
IL274066B (en)	2022-07-01
DK3317281T3 (en)	2020-06-15
RS60411B1 (en)	2020-07-31
SI3613745T1 (en)	2021-12-31
AU2020277123A1 (en)	2020-12-24
US20190337949A1 (en)	2019-11-07
SI3954690T1 (en)	2023-07-31
KR20240115937A (en)	2024-07-26
RU2018103913A3 (en)	2019-12-31
ES2895802T3 (en)	2022-02-22
LT3613745T (en)	2021-10-11
CN113480542A (en)	2021-10-08
CY1124815T1 (en)	2022-11-25
JP2022120156A (en)	2022-08-17
LT3317281T (en)	2020-07-27
RU2018103913A (en)	2019-08-02
US20200255437A1 (en)	2020-08-13
MD3317281T2 (en)	2020-07-31
EP3317281A1 (en)	2018-05-09
DK3954690T3 (en)	2023-06-06
HUE056008T2 (en)	2022-01-28
SMT202300165T1 (en)	2023-07-20
MA50817A (en)	2021-04-21
DK3613745T3 (en)	2021-10-18
US9796721B2 (en)	2017-10-24
US20170029428A1 (en)	2017-02-02
LT3954690T (en)	2023-05-25
ES2797987T3 (en)	2020-12-04
JP7091494B2 (en)	2022-06-27
MX378495B (en)	2025-03-11
HK1250511A1 (en)	2018-12-21
CY1124519T1 (en)	2022-03-24
MX2020014163A (en)	2022-09-29
US10640509B2 (en)	2020-05-05
EP4209493A1 (en)	2023-07-12
ZA202000300B (en)	2022-03-30
US20240199622A1 (en)	2024-06-20
IL256633A (en)	2018-02-28
FI3954690T3 (en)	2023-05-31
ZA201800329B (en)	2022-04-28
AU2022291635B2 (en)	2024-06-27
PL3954690T3 (en)	2023-08-14
EP3613745A1 (en)	2020-02-26
CL2017003445A1 (en)	2018-05-11
IL256633B (en)	2020-05-31
JP6829215B2 (en)	2021-02-10
US11059829B2 (en)	2021-07-13
PT3954690T (en)	2023-06-06
HRP20211511T1 (en)	2021-12-24
RS64195B1 (en)	2023-06-30
IL274066A (en)	2020-06-30
AU2022291635A1 (en)	2023-02-02
EP3954690A1 (en)	2022-02-16
CY1126103T1 (en)	2023-11-15
EP3613745B1 (en)	2021-09-01
CN108349978A (en)	2018-07-31

Publication	Publication Date	Title
IL274066A (en)	2020-06-30	Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
IL262964B (en)	2021-06-30	Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
IL262003A (en)	2018-10-31	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
SI3699181T1 (en)	2023-06-30	Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
PT3041475T (en)	2025-01-07	Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them and methods of their use